ArticleThe Journal of surgical research2021
Presentation, Management, and Prognosis of Primary Gastrointestinal Melanoma: A Population-Based Study.
Article in The Journal of surgical research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 28 citations in OpenAlex.
- The Development and Validation of a Nomogram for Predicting Cancer-Specific Survival and a Risk Stratification System for Patients with Primary Gastrointestinal Melanoma.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2023Trial
- Primary melanoma of the gastrointestinal tract.World journal of gastroenterology · 2026Review
- Ileal malignant melanoma presenting with severe iron-deficiency anemia and active small-bowel bleeding: primary intestinal melanoma versus metastasis - a case report and narrative review.Frontiers in oncology · 2026Article
- Machine learning prediction of overall survival in patients with primary gastrointestinal melanoma.Translational cancer research · 2025Article
- From the Skin to Small Bowel: Metastatic Melanoma as a Hidden Source of Gastrointestinal Bleeding.Cureus · 2025Article
- Anorectal Malignant Melanoma: Diagnostic Pitfalls and Prognostic Insights from a Single-Center Retrospective Analysis.Diagnostics (Basel, Switzerland) · 2025Article
- Review
- Case Report: Surgery combined with targeted therapy for metastatic anorectal malignant mucosal melanoma.Frontiers in oncology · 2025Article
- Long term survival following cryoablation with adjuvant Toripalimab for anorectal malignant melanoma: a case report.Frontiers in oncology · 2025Article
- Small bowel melanoma causing obstruction: A case report and a literature review.International journal of surgery case reports · 2024Article
- HOPX is a tumor-suppressive biomarker that corresponds to T cell infiltration in skin cutaneous melanoma.Cancer cell international · 2023Article
- Article
- Metastatic Malignant Melanoma of the Gastrointestinal Tract: Too Dark to be Seen?GE Portuguese journal of gastroenterology · 2023Article
- A case of long-term survival treated with three metastasectomies and two subsequent adjuvant nivolumab therapies for recurrent malignant melanoma of the esophagus.Surgical case reports · 2022Article
- Epidemiology and outcomes of gastrointestinal mucosal melanomas: a national database analysis.BMC gastroenterology · 2022Article
- Aetiology and Pathogenesis of Cutaneous Melanoma: Current Concepts and Advances.International journal of molecular sciences · 2021Review
- Article
- Primary gallbladder melanoma - a rare entity or a diagnostic pitfall?Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologieReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundPrimary gastrointestinal (GI) melanomas, compared with cutaneous melanomas, have a much lower incidence. As a result, there is a paucity of data regarding their presentation, treatment, and prognosis. The aim of this study was to analyze the incidence, patient characteristics, treatment patterns, and survival of primary GI melanomas in comparison with cutaneous melanomas using a population-based cohort.
methodsPatients diagnosed with primary GI and cutaneous melanomas were identified from Surveillance, Epidemiology, and End Results 1973-2016 data.
resultsA total of 872 primary GI melanomas and 319,327 cutaneous melanomas were identified. GI melanoma incidence increased by an annual percent change of 1.82 (P < 0.05) during the study period. The most common sites for GI melanoma were the anus (50%) and rectum (34%). Compared to cutaneous melanoma, patients diagnosed with GI melanomas were older, women (58% versus 45%), non-White (16% versus 6%), and presented with a higher stage (36% versus 4% distant stage, all P < 0.001). GI melanomas had significantly worse cancer-specific survival (CSS) than cutaneous melanoma. Despite the poor prognosis, the CSS has increased in recent years. Among patients with anorectal melanomas, local excision with chemotherapy and/or radiation had a similar CSS compared with those with major surgery only.
conclusionsDespite a steady increasing incidence since 1975, GI melanomas are rare, present with advanced stages, and have worse outcomes than cutaneous melanomas. The improved prognosis of these tumors in recent years might reflect the impact of novel targeted treatments and the more common use of local tumor excision over major resections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.